(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 60.98% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Bridgebio Pharma's revenue in 2026 is $579,958,000.On average, 26 Wall Street analysts forecast BBIO's revenue for 2026 to be $193,246,494,419, with the lowest BBIO revenue forecast at $162,079,094,980, and the highest BBIO revenue forecast at $221,323,203,460. On average, 24 Wall Street analysts forecast BBIO's revenue for 2027 to be $324,346,216,752, with the lowest BBIO revenue forecast at $266,763,011,604, and the highest BBIO revenue forecast at $474,180,066,882.
In 2028, BBIO is forecast to generate $478,097,291,722 in revenue, with the lowest revenue forecast at $391,918,345,242 and the highest revenue forecast at $599,139,539,278.